JAK / Stat
-
ZM 449829
Catalog No. A15366 -
Peficitinib (ASP015K, JNJ-54781532)
Catalog No. A14438 -
NS-018
Catalog No. A16224 -
NS-018 hydrochloride
Catalog No. A16225 -
NS-018 maleate
Catalog No. A16226 JAK2 抑制剂NS-018 maleate是在Ba/F3-JAK2V617F细胞中具有ATP竞争性的JAK2小分子抑制剂,IC50为470nM。与其他JAK家族激酶(例如JAK1,JAK3和酪氨酸激酶2)相比,对JAK2的选择性高30-50倍。 了解更多 -
ZM39923
Catalog No. A16227 -
Delgocitinib
Catalog No. A19234 JAK inhibitorDelgocitinib is a novel and specific JAK inhibitor with IC50s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JAK3 and Tyk2, respectively. 了解更多 -
Gusacitinib
Catalog No. A19883 SYK/JAK inhibitorGusacitinib (ASN-002) is a potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 values of 5-46 nM. 了解更多 -
Cyt387 (Momelotinib)
Catalog No. A10263 JAK 抑制剂Cyt387 (Momelotinib)是Janus激酶JAK1和JAK2的抑制剂,可作为ATP竞争者,IC50值分别为11和18 nM。 了解更多 -
Pacritinib (SB1518)
Catalog No. A12694 JAK2/FLT3 抑制剂Pacritinib (SB1518)是Janus激酶2(JAK2)和JAK2突变体JAK2V617F的口服生物利用抑制剂,无细胞试验中IC50分别为23和22 nM,具有潜在的抗肿瘤活性。Pacritinib与JAK2竞争ATP结合,这可能导致抑制JAK2活化,抑制JAK-STAT信号传导途径以及半胱天冬酶依赖性凋亡。 了解更多 -
INCB39110 (Itacitinib)
Catalog No. A14390 JAK1 抑制剂INCB39110 (Itacitinib)是一种有效的JAK1酪氨酸激酶抑制剂,目前正在II期试验中,用于治疗类风湿关节炎,骨髓纤维化,类风湿关节炎和斑块状牛皮癣。 了解更多 -
CP-690550 (Tofacitinib citrate)
Catalog No. A10241 JAK3 抑制剂CP-690550 (Tofacitinib citrate)是口服的高选择性Janus激酶(JAK)酶抑制剂。 了解更多 -
PF-03394197 (oclacitinib)
Catalog No. A13082 -
INCB018424 (Ruxolitinib)
Catalog No. A11041 JAK1/2 抑制剂INCB018424 (Ruxolitinib)是有效和选择性的Janus相关激酶JAK1/2抑制剂,对JAK1,JAK2和JAK3的IC50分别为2.7、4.5和332 nM。 了解更多